These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 35212383)

  • 1. Detection of tumor-specific DNA methylation markers in the blood of patients with pituitary neuroendocrine tumors.
    Herrgott GA; Asmaro KP; Wells M; Sabedot TS; Malta TM; Mosella MS; Nelson K; Scarpace L; Barnholtz-Sloan JS; Sloan AE; Selman WR; deCarvalho AC; Poisson LM; Mukherjee A; Robin AM; Lee IY; Snyder J; Walbert T; Rosenblum M; Mikkelsen T; Bhan A; Craig J; Kalkanis S; Rock J; Noushmehr H; Castro AV
    Neuro Oncol; 2022 Jul; 24(7):1126-1139. PubMed ID: 35212383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA Methylation of Tumor Suppressor Genes in Pituitary Neuroendocrine Tumors.
    García-Martínez A; Sottile J; Sánchez-Tejada L; Fajardo C; Cámara R; Lamas C; Barberá VM; Picó A
    J Clin Endocrinol Metab; 2019 Apr; 104(4):1272-1282. PubMed ID: 30423170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA methylation-based signatures classify sporadic pituitary tumors according to clinicopathological features.
    Mosella MS; Sabedot TS; Silva TC; Malta TM; Dezem FS; Asmaro KP; Wells M; Mukherjee A; Poisson LM; Snyder J; deCarvalho AC; Walbert T; Aho T; Kalkanis S; Elias PC; Antonini SR; Rock J; Noushmehr H; Castro M; Castro AV
    Neuro Oncol; 2021 Aug; 23(8):1292-1303. PubMed ID: 33631002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenomic and somatic mutations of pituitary tumors with clinical and pathological correlations in 111 patients.
    Guaraldi F; Morandi L; Zoli M; Mazzatenta D; Righi A; Evangelisti S; Ambrosi F; Tonon C; Giannini C; Lloyd RV; Asioli S
    Clin Endocrinol (Oxf); 2022 Dec; 97(6):763-772. PubMed ID: 36161330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression levels of β-catenin are associated with invasive behavior of both functional and non-functional pituitary neuroendocrine tumor (PitNET).
    Taghavi SF; Ghorbani M; Panahi M; Nazem S; Karimi M; Salimi V; Tavakoli-Yaraki M
    Mol Biol Rep; 2023 Aug; 50(8):6425-6434. PubMed ID: 37326745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PITX2 Expression in Non-functional Pituitary Neuroendocrine Tumor with Cavernous Sinus Invasion.
    Tamura R; Ohara K; Morimoto Y; Kosugi K; Oishi Y; Sato M; Yoshida K; Toda M
    Endocr Pathol; 2019 Jun; 30(2):81-89. PubMed ID: 30903445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pangenomic Classification of Pituitary Neuroendocrine Tumors.
    Neou M; Villa C; Armignacco R; Jouinot A; Raffin-Sanson ML; Septier A; Letourneur F; Diry S; Diedisheim M; Izac B; Gaspar C; Perlemoine K; Verjus V; Bernier M; Boulin A; Emile JF; Bertagna X; Jaffrezic F; Laloe D; Baussart B; Bertherat J; Gaillard S; Assié G
    Cancer Cell; 2020 Jan; 37(1):123-134.e5. PubMed ID: 31883967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency and Role of CDKN2A Deletion in High-Risk Pituitary Neuroendocrine Tumors.
    Kara M; Tokat F; Pamir MN; Danyeli AE
    Endocr Pathol; 2020 Jun; 31(2):166-173. PubMed ID: 32157655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.
    Mete O; Alshaikh OM; Cintosun A; Ezzat S; Asa SL
    Endocr Pathol; 2018 Dec; 29(4):332-338. PubMed ID: 30215160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. scRNA sequencing technology for PitNET studies.
    Asaad W; Utkina M; Shcherbakova A; Popov S; Melnichenko G; Mokrysheva N
    Front Endocrinol (Lausanne); 2024; 15():1414223. PubMed ID: 39114291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pituitary Tumors: Genetic and Molecular Factors Underlying Pathogenesis and Clinical Behavior.
    Spada A; Mantovani G; Lania AG; Treppiedi D; Mangili F; Catalano R; Carosi G; Sala E; Peverelli E
    Neuroendocrinology; 2022; 112(1):15-33. PubMed ID: 33524974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Epidemiology, Genetics and Pathogenesis of Pituitary Neuroendocrine Tumors].
    Suzuki K; Tahara S
    No Shinkei Geka; 2023 Jul; 51(4):593-606. PubMed ID: 37491056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA Methylation Pattern in Somatotroph Pituitary Neuroendocrine Tumors.
    Kober P; Rymuza J; Baluszek S; Maksymowicz M; Nyc A; Mossakowska BJ; Zieliński G; Kunicki J; Bujko M
    Neuroendocrinology; 2024; 114(1):51-63. PubMed ID: 37699356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Annotation of pituitary neuroendocrine tumors with genome-wide expression analysis.
    Tebani A; Jotanovic J; Hekmati N; Sivertsson Å; Gudjonsson O; Edén Engström B; Wikström J; Uhlèn M; Casar-Borota O; Pontén F
    Acta Neuropathol Commun; 2021 Nov; 9(1):181. PubMed ID: 34758873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative Acetylomics Revealed Acetylation-Mediated Molecular Pathway Network Changes in Human Nonfunctional Pituitary Neuroendocrine Tumors.
    Wen S; Li J; Yang J; Li B; Li N; Zhan X
    Front Endocrinol (Lausanne); 2021; 12():753606. PubMed ID: 34712204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of the 2022 WHO Classification of Pituitary Tumors.
    Asa SL; Mete O; Perry A; Osamura RY
    Endocr Pathol; 2022 Mar; 33(1):6-26. PubMed ID: 35291028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two Pituitary Neuroendocrine Tumors (PitNETs) with Very High Proliferation and TP53 Mutation - High-Grade PitNET or PitNEC?
    Saeger W; Mawrin C; Meinhardt M; Wefers AK; Jacobsen F
    Endocr Pathol; 2022 Jun; 33(2):257-262. PubMed ID: 34669159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple tumorous lesions of the pituitary gland.
    Schöning JV; Flitsch J; Lüdecke DK; Fahlbusch R; Buchfelder M; Buslei R; Knappe UJ; Bergmann M; Schulz-Schaeffer WJ; Herms J; Glatzel M; Saeger W
    Hormones (Athens); 2022 Dec; 21(4):653-663. PubMed ID: 35947342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The expression of neural cell adhesion molecule and the microenvironment of pituitary neuroendocrine tumours.
    Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Grieve J; Dorward N; Mendoza N; Nair R; Muquit S; Grossman AB; Korbonits M
    J Neuroendocrinol; 2021 Dec; 33(12):e13052. PubMed ID: 34708902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of the enhancer RNAs related to tumorgenesis of pituitary neuroendocrine tumors.
    Wang L; Wei C; Wang Y; Huang N; Zhang T; Dai Y; Xue L; Lin S; Wu ZB
    Front Endocrinol (Lausanne); 2023; 14():1149997. PubMed ID: 37534217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.